Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 114,234 shares, an increase of 1,418.5% from the June 15th total of 7,523 shares. Approximately 7.6% of the company’s stock are short sold. Based on an average daily trading volume, of 53,894 shares, the short-interest ratio is presently 2.1 days.

Global X Genomics & Biotechnology ETF Price Performance

GNOM traded down $1.89 during trading on Friday, hitting $56.65. The company had a trading volume of 33,529 shares, compared to its average volume of 14,357. Global X Genomics & Biotechnology ETF has a 1-year low of $34.04 and a 1-year high of $59.48. The company has a market cap of $85.54 million, a PE ratio of -24.21 and a beta of 1.16. The business has a 50-day moving average of $50.36 and a 200-day moving average of $47.61.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently announced a dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were given a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is presently -27.35%.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Several large investors have recently modified their holdings of GNOM. IFP Advisors Inc lifted its position in shares of Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after purchasing an additional 489 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after buying an additional 4,615 shares during the last quarter. Sei Investments Co. increased its holdings in Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares during the last quarter. Wealth Management Partners LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the first quarter valued at approximately $244,000. Finally, Creative Financial Designs Inc. ADV raised its stake in Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after buying an additional 481 shares in the last quarter. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.